Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 2/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.32 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21052114 | 1.00 | LAP3 (0.33) | LAP3CACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL4751639 | 0.84 | LAP3 (0.40) | LAP3CACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL8094046 | 0.84 | LAP3 (0.40) | LAP3CACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL3787479 | 0.81 | — | — | |
| SCHEMBL11200302 | 0.81 | POLB (0.32) | — | |
| SCHEMBL15717745 | 0.80 | — | — | |
| SCHEMBL16994559 | 0.79 | — | — | |
| SCHEMBL1526590 | 0.79 | — | — | |
| SCHEMBL1526593 | 0.79 | — | — | |
| SCHEMBL18291171 | 0.79 | CA2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673869-B2 | 4-oxazolidinone antimicrobial agents | NORTH CAROLINA STATE UNIVERSITY (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673869-B2 | 4-oxazolidinone antimicrobial agents | NORTH CAROLINA STATE UNIVERSITY (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673869-B2 | 4-oxazolidinone antimicrobial agents | NORTH CAROLINA STATE UNIVERSITY (US) | 2023-06-13 | — | — | US | disclosed |
| US-20210323934-A1 | 4-OXAZOLIDINONE ANTIMICROBIAL AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-21 | — | — | US | disclosed |
| US-10844025-B2 | 4-oxazolidinone antimicrobial agents | NORTH CAROLINA STATE UNIVERSITY (US) | 2020-11-24 | — | — | US | disclosed |
| US-10844025-B2 | 4-oxazolidinone antimicrobial agents | NORTH CAROLINA STATE UNIVERSITY (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190177285-A1 | 4-OXAZOLIDINONE ANTIMICROBIAL AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-06-13 | — | — | US | disclosed |
| US-20190177285-A1 | 4-OXAZOLIDINONE ANTIMICROBIAL AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177285-A1 | 4-OXAZOLIDINONE ANTIMICROBIAL AGENTS | OXA1L, MMP17, MMP2 | LAP3 2662/4885CACNA2D1 1572/4885CACNB3 2800/4885 |
| US-10844025-B2 | 4-oxazolidinone antimicrobial agents | OXA1L, MMP17, MMP2 | LAP3 2662/4885CACNA2D1 1572/4885CACNB3 2800/4885 |
| US-11673869-B2 | 4-oxazolidinone antimicrobial agents | OXA1L, MMP17, MMP2 | LAP3 2662/4885CACNA2D1 1572/4885CACNB3 2800/4885 |
| US-20210323934-A1 | 4-OXAZOLIDINONE ANTIMICROBIAL AGENTS | OXA1L, MMP17, MMP2 | LAP3 2662/4885CACNA2D1 1572/4885CACNB3 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.